» Articles » PMID: 36836098

Advancing Precision Medicine for the Diagnosis and Treatment of Acute Respiratory Distress Syndrome

Overview
Journal J Clin Med
Specialty General Medicine
Date 2023 Feb 25
PMID 36836098
Authors
Affiliations
Soon will be listed here.
Abstract

Acute respiratory distress syndrome (ARDS) is a common and life-threatening cause of respiratory failure. Despite decades of research, there are no effective pharmacologic therapies to treat this disease process and mortality remains high. The shortcomings of prior translational research efforts have been increasingly attributed to the heterogeneity of this complex syndrome, which has led to an increased focus on elucidating the mechanisms underlying the interpersonal heterogeneity of ARDS. This shift in focus aims to move the field towards personalized medicine by defining subgroups of ARDS patients with distinct biology, termed endotypes, to quickly identify patients that are most likely to benefit from mechanism targeted treatments. In this review, we first provide a historical perspective and review the key clinical trials that have advanced ARDS treatment. We then review the key challenges that exist with regards to the identification of treatable traits and the implementation of personalized medicine approaches in ARDS. Lastly, we discuss potential strategies and recommendations for future research that we believe will aid in both understanding the molecular pathogenesis of ARDS and the development of personalized treatment approaches.

Citing Articles

Aerosol of Enoximone/Hydroxypropyl-β-Cyclodextrin Inclusion Complex, Biopharmaceutical Evidence for ARDS Applicability.

Migone C, Grassiri B, Vizzoni L, Fabiano A, Ferro B, Zambito Y Pharmaceutics. 2024; 16(9).

PMID: 39339257 PMC: 11435411. DOI: 10.3390/pharmaceutics16091221.


Integrating hot topics and implementation of treatable traits in asthma.

Gibson P, McDonald V Eur Respir J. 2024; 64(6).

PMID: 39255992 PMC: 11618818. DOI: 10.1183/13993003.00861-2024.


A Case of Acute Respiratory Distress Syndrome Following Non-thoracic Trauma in a Patient With Idiopathic Pulmonary Fibrosis.

Hirooka Y, Ota S, Torizawa N, Maekawa C, Yanagawa Y Cureus. 2024; 16(6):e63467.

PMID: 39077261 PMC: 11285813. DOI: 10.7759/cureus.63467.


Incidence, mortality, and predictive factors associated with acute respiratory distress syndrome in multiple trauma patients living in high-altitude areas: a retrospective study in Shigatse.

Tu D, Ji L, Cao Q, Ley T, Duo S, Cheng N PeerJ. 2024; 12:e17521.

PMID: 38903881 PMC: 11188934. DOI: 10.7717/peerj.17521.


Lung ultrasound is associated with distinct clinical phenotypes in COVID-19 ARDS: A retrospective observational study.

Dayan R, Blau M, Taylor J, Hasidim A, Galante O, Almog Y PLoS One. 2024; 19(6):e0304508.

PMID: 38829891 PMC: 11146726. DOI: 10.1371/journal.pone.0304508.


References
1.
Calfee C, Delucchi K, Parsons P, Thompson B, Ware L, Matthay M . Subphenotypes in acute respiratory distress syndrome: latent class analysis of data from two randomised controlled trials. Lancet Respir Med. 2014; 2(8):611-20. PMC: 4154544. DOI: 10.1016/S2213-2600(14)70097-9. View

2.
Berry S, Connor J, Lewis R . The platform trial: an efficient strategy for evaluating multiple treatments. JAMA. 2015; 313(16):1619-20. DOI: 10.1001/jama.2015.2316. View

3.
Dichter J, Devereaux A, Sprung C, Mukherjee V, Persoff J, Baum K . Mass Critical Care Surge Response During COVID-19: Implementation of Contingency Strategies - A Preliminary Report of Findings From the Task Force for Mass Critical Care. Chest. 2021; 161(2):429-447. PMC: 8420082. DOI: 10.1016/j.chest.2021.08.072. View

4.
McAuley D, Laffey J, OKane C, Perkins G, Mullan B, Trinder T . Simvastatin in the acute respiratory distress syndrome. N Engl J Med. 2014; 371(18):1695-703. DOI: 10.1056/NEJMoa1403285. View

5.
Matthay M, McAuley D, Ware L . Clinical trials in acute respiratory distress syndrome: challenges and opportunities. Lancet Respir Med. 2017; 5(6):524-534. DOI: 10.1016/S2213-2600(17)30188-1. View